Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study.
Márquez-Rodas I, Martín González M, Nagore E, Gómez-Fernández C, Avilés-Izquierdo JA, Maldonado-Seral C, Soriano V, Majem-Tarruella M, Palomar V, Maseda R, Martín-Carnicero A, Puertolas T, Godoy E, Cerezuela P, Ochoa de Olza M, Campos B, Perez-Ruiz E, Soria A, Gil-Arnaiz I, Gonzalez-Cao M, Galvez E, Arance A, Belon J, de la Cruz-Merino L, Martín-Algarra S; Spanish Multidisciplinary Group of Melanoma (GEM). Márquez-Rodas I, et al. PLoS One. 2015 Apr 13;10(4):e0124239. doi: 10.1371/journal.pone.0124239. eCollection 2015. PLoS One. 2015. PMID: 25874698 Free PMC article.
Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial.
Moura DS, Lopez-Marti JM, Benesova I, de Andrea C, di Lernia D, Lacerenza S, Mondaza-Hernandez JL, Martin-Ruiz M, Ramirez-Calvo M, Grignani G, Martinez-Trufero J, Redondo A, Valverde C, Stacchiotti S, Lopez-Pousa A, Lopez-Guerrero JA, Gutierrez A, Encinas-Tobajas V, Hindi N, Sangiolo D, Lopez-Martin JA, Strizova ZO, Martin-Broto J. Moura DS, et al. Among authors: lopez martin ja. Clin Cancer Res. 2024 Nov 15;30(22):5192-5206. doi: 10.1158/1078-0432.CCR-24-1782. Clin Cancer Res. 2024. PMID: 39283727
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours.
Yap TA, Cortes-Funes H, Shaw H, Rodriguez R, Olmos D, Lal R, Fong PC, Tan DS, Harris D, Capdevila J, Coronado C, Alfaro V, Soto-Matos A, Fernández-Teruel C, Siguero M, Tabernero JM, Paz-Ares L, de Bono JS, López-Martin JA. Yap TA, et al. Br J Cancer. 2012 Apr 10;106(8):1379-85. doi: 10.1038/bjc.2012.99. Br J Cancer. 2012. PMID: 22491421 Free PMC article. Clinical Trial.
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R. Angevin E, et al. Clin Cancer Res. 2014 Apr 15;20(8):2192-204. doi: 10.1158/1078-0432.CCR-13-2200. Epub 2014 Feb 21. Clin Cancer Res. 2014. PMID: 24563479 Clinical Trial.
Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.
Agulló-Ortuño MT, García-Ruiz I, Díaz-García CV, Enguita AB, Pardo-Marqués V, Prieto-García E, Ponce S, Iglesias L, Zugazagoitia J, López-Martín JA, Paz-Ares L, Nuñez JA. Agulló-Ortuño MT, et al. Cancer Chemother Pharmacol. 2020 Mar;85(3):525-535. doi: 10.1007/s00280-019-04008-9. Epub 2019 Dec 12. Cancer Chemother Pharmacol. 2020. PMID: 31832811
84 results